Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | BCEL |
---|---|---|
09:32 ET | 2247 | 0.0901 |
09:52 ET | 78271 | 0.0901 |
09:54 ET | 5196 | 0.089 |
09:57 ET | 5000 | 0.09318 |
09:59 ET | 5600 | 0.09318 |
10:03 ET | 5000 | 0.09318 |
10:10 ET | 1000 | 0.0901 |
11:40 ET | 100 | 0.0902 |
01:53 ET | 100 | 0.0901 |
02:18 ET | 145 | 0.09178 |
02:36 ET | 1000 | 0.093 |
02:38 ET | 7000 | 0.093 |
02:40 ET | 32000 | 0.093 |
02:45 ET | 10278 | 0.09514 |
03:25 ET | 137 | 0.09304 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Atreca Inc | 3.7M | 0.0x | --- |
Biophytis SA | 3.4M | -0.1x | --- |
Altamira Therapeutics Ltd | 3.3M | -0.1x | --- |
GeoVax Labs Inc | 3.8M | -0.1x | --- |
Revelation Biosciences Inc | 3.6M | 0.1x | --- |
Phio Pharmaceuticals Corp | 3.7M | -0.1x | --- |
Atreca, Inc. is a clinical-stage biopharmaceutical company. The Company is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. It commenced clinical development of ATRC-101 with a Phase Ib clinical trial evaluating ATRC-101 as a monotherapy in patients with select solid tumors and opens a new cohort to evaluate ATRC-101 in combination with pembrolizumab, a PD-1 checkpoint inhibitor. It is also advancing additional product candidates using its discovery platform. Its oncology programs include APN-497444, an ADC against a tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.7M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 39.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.03 |
EPS | $-2.49 |
Book Value | $2.01 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.